Pricing
  1. US-listed companies
  2. HALOZYME THERAPEUTICS, INC.
  3. Financials
  4. Total current liabilities

HALOZYME THERAPEUTICS, INC. (HALO)

Market cap
$7.9B
P/E ratio
SummaryFinancials
Period EndTotal current liabilities (Million USD)YoY (%)
Dec 31, 2024139+23.65%
Dec 31, 2023112-13.99%
Dec 31, 2022131+11.65%
Dec 31, 2021117-72.20%
Dec 31, 2020421+392.06%
Dec 31, 201986-42.66%
Dec 31, 2018149+13.73%
Dec 31, 2017131+140.59%
Dec 31, 201655-12.60%
Dec 31, 201562+156.70%
Dec 31, 201424-4.41%
Dec 31, 201325+34.34%
Dec 31, 201219+9.50%
Dec 31, 201117

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat